Cargando…

Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study

BACKGROUND: Information lacks about institutional stakeholders’ perspectives on management approaches of multidrug-resistant bacterial organism in end-of-life situations. The term “institutional stakeholder” includes persons in leading positions with responsibility in hospitals’ multidrug-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Heckel, Maria, Herbst, Franziska A, Adelhardt, Thomas, Tiedtke, Johanna M, Sturm, Alexander, Stiel, Stephanie, Ostgathe, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633291/
https://www.ncbi.nlm.nih.gov/pubmed/29042761
http://dx.doi.org/10.2147/CIA.S138429
_version_ 1783269864206499840
author Heckel, Maria
Herbst, Franziska A
Adelhardt, Thomas
Tiedtke, Johanna M
Sturm, Alexander
Stiel, Stephanie
Ostgathe, Christoph
author_facet Heckel, Maria
Herbst, Franziska A
Adelhardt, Thomas
Tiedtke, Johanna M
Sturm, Alexander
Stiel, Stephanie
Ostgathe, Christoph
author_sort Heckel, Maria
collection PubMed
description BACKGROUND: Information lacks about institutional stakeholders’ perspectives on management approaches of multidrug-resistant bacterial organism in end-of-life situations. The term “institutional stakeholder” includes persons in leading positions with responsibility in hospitals’ multidrug-resistant bacterial organism management. They have great influence on how strategies on multidrug-resistant bacterial organism management approaches in institutions of the public health system are designed. This study targeted institutional stakeholders’ individual perspectives on multidrug-resistant bacterial organism colonization or infection and isolation measures at the end of life. METHODS: Between March and December 2014, institutional stakeholders of two study centers, a German palliative care unit and a geriatric ward, were queried in semistructured interviews. Interviews were audiotaped, transcribed verbatim, and analyzed qualitatively with the aid of the software MAXQDA for qualitative data analysis using principles of Grounded Theory. In addition, two external stakeholders were interviewed to enrich data. RESULTS: Key issues addressed by institutional stakeholders (N=18) were the relevance of multidrug-resistant bacterial organism in palliative and geriatric care, contradictions between hygiene principles and patients’ and family caregivers’ needs and divergence from standards, frame conditions, and reflections on standardization of multidrug-resistant bacterial organism end-of-life care procedures. Results show that institutional stakeholders face a dilemma between their responsibility in protecting third persons and ensuring patients’ quality of life. Until further empirical evidence establishes a clear multidrug-resistant bacterial organism management approach in end-of-life care, stakeholders suggest a case-based approach. CONCLUSION: The institutional stakeholders’ perspectives and their suggestion of a case-based approach advance the development process of a patient-, family-, staff-, and institutional-centered approach of how to deal with multidrug-resistant bacterial organism-positive patients in end-of-life care. Institutional stakeholders play an important role in the implementation of recommendations following this approach.
format Online
Article
Text
id pubmed-5633291
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56332912017-10-17 Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study Heckel, Maria Herbst, Franziska A Adelhardt, Thomas Tiedtke, Johanna M Sturm, Alexander Stiel, Stephanie Ostgathe, Christoph Clin Interv Aging Original Research BACKGROUND: Information lacks about institutional stakeholders’ perspectives on management approaches of multidrug-resistant bacterial organism in end-of-life situations. The term “institutional stakeholder” includes persons in leading positions with responsibility in hospitals’ multidrug-resistant bacterial organism management. They have great influence on how strategies on multidrug-resistant bacterial organism management approaches in institutions of the public health system are designed. This study targeted institutional stakeholders’ individual perspectives on multidrug-resistant bacterial organism colonization or infection and isolation measures at the end of life. METHODS: Between March and December 2014, institutional stakeholders of two study centers, a German palliative care unit and a geriatric ward, were queried in semistructured interviews. Interviews were audiotaped, transcribed verbatim, and analyzed qualitatively with the aid of the software MAXQDA for qualitative data analysis using principles of Grounded Theory. In addition, two external stakeholders were interviewed to enrich data. RESULTS: Key issues addressed by institutional stakeholders (N=18) were the relevance of multidrug-resistant bacterial organism in palliative and geriatric care, contradictions between hygiene principles and patients’ and family caregivers’ needs and divergence from standards, frame conditions, and reflections on standardization of multidrug-resistant bacterial organism end-of-life care procedures. Results show that institutional stakeholders face a dilemma between their responsibility in protecting third persons and ensuring patients’ quality of life. Until further empirical evidence establishes a clear multidrug-resistant bacterial organism management approach in end-of-life care, stakeholders suggest a case-based approach. CONCLUSION: The institutional stakeholders’ perspectives and their suggestion of a case-based approach advance the development process of a patient-, family-, staff-, and institutional-centered approach of how to deal with multidrug-resistant bacterial organism-positive patients in end-of-life care. Institutional stakeholders play an important role in the implementation of recommendations following this approach. Dove Medical Press 2017-10-03 /pmc/articles/PMC5633291/ /pubmed/29042761 http://dx.doi.org/10.2147/CIA.S138429 Text en © 2017 Heckel et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Heckel, Maria
Herbst, Franziska A
Adelhardt, Thomas
Tiedtke, Johanna M
Sturm, Alexander
Stiel, Stephanie
Ostgathe, Christoph
Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title_full Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title_fullStr Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title_full_unstemmed Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title_short Understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
title_sort understanding institutional stakeholders’ perspectives on multidrug-resistant bacterial organism at the end of life: a qualitative study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633291/
https://www.ncbi.nlm.nih.gov/pubmed/29042761
http://dx.doi.org/10.2147/CIA.S138429
work_keys_str_mv AT heckelmaria understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT herbstfranziskaa understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT adelhardtthomas understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT tiedtkejohannam understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT sturmalexander understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT stielstephanie understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy
AT ostgathechristoph understandinginstitutionalstakeholdersperspectivesonmultidrugresistantbacterialorganismattheendoflifeaqualitativestudy